This month
phase 3 is starting now — and the most interesting data readout arrives first
Last month at EASL 2026, Altimmune's pemvidutide was named Best of EASL in the congress's summary deck, based on 48-week Phase 2b data from the IMPACT trial in metabolic dysfunction-associated steatohepatitis — the liver disease more commonly called MASH. The results showed 32.4% of patients on the higher dose achieved meaningful improvements in two simultaneous fibrosis markers at 48 weeks, versus 3.2% on placebo. That is a signal the FDA had already been watching: pemvidutide holds Breakthrough Therapy Designation for MASH and Fast Track status for alcohol use disorder. What the coverage mostly ignored is that the most time-sensitive data readout from pemvidutide in 2026 is not about the liver. It is about drinking. The RECLAIM Phase 2 trial, which enrolled approximately 100 people with alcohol use disorder and completed enrollment ahead of schedule in November 2025, is expected to release topline results in the third quarter of 2026 — a window that opens this month. Meanwhile, the PERFORMA Phase 3 MASH trial is also slated to initiate in the second half of 2026. July is the start of both countdowns.
The actual mechanism
a balanced GLP-1/glucagon dual agonist — and why the balance matters
Most of the drug names dominating the current metabolic conversation are GLP-1 focused: semaglutide hits one receptor, tirzepatide adds GIP, retatrutide reaches three. Pemvidutide runs GLP-1 and glucagon receptor activity in a balanced 1:1 ratio, and the balance is the design choice that matters. GLP-1 receptor activation handles the appetite and incretin side — reducing food intake, slowing gastric emptying, triggering glucose-dependent insulin release. Glucagon receptor activation in the liver drives hepatic fat mobilization — the mechanism hypothesized to explain the MASH data, where liver fat reduction is the central question. The GLP-1 side of the receptor pharmacology also connects to something else entirely: the mesolimbic reward circuit. GLP-1 receptors are expressed in dopamine pathways involved in reward and craving, and GLP-1 activity has been shown to modulate alcohol self-administration in preclinical models and, increasingly, in randomized human trials. That is the biology behind the RECLAIM trial. A peptide designed for a liver disease may also carry mechanism-level activity in the same brain circuits that drive addiction.
The public framing
it gets compared to tirzepatide — that comparison misses where the data actually sits
In the metabolic-drug tracking community, pemvidutide gets framed primarily as another next-wave obesity candidate: a GLP-1/glucagon compound that might produce better weight loss than tirzepatide by engaging the glucagon pathway more aggressively. The weight data from IMPACT is real — 7.5% weight reduction at 48 weeks, triglycerides down 23.7%, total cholesterol down 15.4% — and the absence of a weight-loss plateau at 48 weeks is a notable finding in a category where plateau timing is a meaningful clinical variable. But the pure weight-comparison frame misses two things. First, the primary evidence base for pemvidutide is MASH-specific, not general obesity. The IMPACT trial enrolled biopsy-confirmed MASH patients with F2-F3 fibrosis staging — not the general overweight population that makes up most Ozempic and Wegovy users. Second, the AUD application represents a genuinely novel pharmacological hypothesis — not just an incretin refinement story. Pemvidutide's actual scope is wider than its common framing, and Q3 2026 is where that starts to become apparent.
What the data says
controlled Phase 2b MASH data, FDA recognition, and an alcohol trial about to read out
The IMPACT Phase 2b trial is the clinical foundation. It was randomized, double-blind, placebo-controlled, and ran 48 weeks in 212 participants with biopsy-confirmed MASH. The primary endpoint combined two non-invasive fibrosis markers — Enhanced Liver Fibrosis score reduction of ≥0.5 and liver stiffness measurement reduction of ≥30%. At 48 weeks, 32.4% of the 1.8 mg arm hit both versus 3.2% on placebo (p<0.0001). Fibrosis regression was also confirmed through AI-based digital pathology analysis. The [PubMed literature on pemvidutide](https://pubmed.ncbi.nlm.nih.gov/?term=pemvidutide) and [ClinicalTrials.gov records](https://clinicaltrials.gov/search?term=pemvidutide) document the growing investigational program across MASH, AUD, and alcohol-associated liver disease. The FDA Breakthrough Therapy Designation for MASH is not approval, but it reflects the agency's preliminary read that early evidence justifies accelerated development for a serious condition with limited treatment options. A 2025 Lancet eClinicalMedicine [meta-analysis on GLP-1 receptor agonists and alcohol consumption](https://www.thelancet.com/journals/eclinm/article/PIIS2589-5370(25)00579-6/fulltext) establishes the biological plausibility of the AUD signal more broadly. The [RECLAIM trial registration](https://clinicaltrials.gov/study/NCT06987513) shows 100 participants randomized to pemvidutide or placebo for 24 weeks, with enrollment completed in November 2025. Topline results are expected in Q3 2026.
Early human — PeptideFactCheck stance
real phase 2b signal and FDA recognition — phase 3 is what closes the gap
Pemvidutide holds the Early human evidence tier on PeptideFactCheck: interesting enough to watch, too early for broad certainty. The IMPACT data is Phase 2b science — controlled, biopsy-confirmed population, statistically significant fibrosis outcomes against placebo. The FDA Breakthrough Therapy Designation for MASH reflects a regulatory read that the signal was worth taking seriously in a disease space where approved treatment options remain limited. What the Early human tier marks is the gap between that signal and a completed Phase 3 trial with an approved label. The PERFORMA Phase 3, if initiated on the planned H2 2026 timeline, will be the clinical event that determines whether the MASH finding holds at registrational scale. The RECLAIM AUD trial will answer the more unexpected question: whether a liver-disease peptide has something real to say about the brain's reward circuitry. Both are clinical questions, not mechanism claims. The [EASL 2026 IMPACT data](https://www.globenewswire.com/news-release/2026/05/28/3303064/0/en/Pemvidutide-Demonstrates-Significant-Metabolic-Improvements-in-Patients-with-MASH-in-New-48-Week-IMPACT-Phase-2b-Data-Presented-at-EASL-2026.html) is the anchor point for July 2026. Phase 3 and RECLAIM are the next chapters — and this summer is when both begin.
Editorial boundary
What this page will not do
It will not provide dosing, cycling, sourcing, injection, or personal medical instructions. The job is to classify claims and explain mechanisms.